Logo

EMA's CHMP Recommends Compassionate Use of Gilead's Remdesivir for COVID-19

Share this

EMA's CHMP Recommends Compassionate Use of Gilead's Remdesivir for COVID-19

Shots:

  • On Apr 02- 2020- EMA’s CHMP has recommended Gilead’s Remdesivir to be used for treating COVID-19 in compassionate use programmes in the EU
  • Compassionate use programmes are intended to provide patients access to therapies that are under development and have not yet received a marketing authorization. The CHMP encourages Gilead to make remdesivir available in a transparent way to those Member States wishing to take part in international clinical studies or treat patients in compassionate use programmes
  • Estonia- Greece- the Netherlands and Romania requested CHMP’s opinion on the conditions under which early access to Remdesivir via compassionate use could be offered to patients with COVID-19

Click here ­to­ read full press release/ article 

 Ref: EMA | Image: Gilead


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions